abstract |
The present specification relates to an APY cyclic peptide having EphA4 antagonist activity, a pharmaceutical composition comprising the EphA4 antagonist, and a disease, disorder, or condition caused by EphA4 in an individual using the APY cyclic peptide or pharmaceutical composition Methods and uses are disclosed. [Selection] Figure 1 |